Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer

In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2‐targeting agents without chemotherapy (CT) in HER2‐positive metastatic breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered a unique opportunity to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Oncol
Autors principals: Montemurro, Filippo, Prat, Aleix, Rossi, Valentina, Valabrega, Giorgio, Sperinde, Jeff, Peraldo-Neia, Caterina, Donadio, Michela, Galván, Patricia, Sapino, Anna, Aglietta, Massimo, Baselga, José, Scaltriti, Maurizio
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2013
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528507/
https://ncbi.nlm.nih.gov/pubmed/24075779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.08.013
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars